ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid Tumors; Announcing First Preclinical Proof of Concept in Proprietary CCR8 Treg Program

ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid Tumors; Announcing First Preclinical Proof of Concept in Proprietary CCR8 Treg Program

  • October 22, 2020

– Strategic focus of immuno-oncology (I-O) portfolio on modulation of tumor microenvironment to enhance T cell influx and activity in immune excluded solid tumors, aspects that immune checkpoint inhibitors do not address.

– Preclinical Proof of Concept for Company’s priority I-O program, aiming at depleting regulatory T cells (Tregs) by targeting C-C motif chemokine receptor 8 (CCR8) 

Initiating lead optimization phase in proprietary CCR8 Treg Program.

Preclinical development of therapeutic antibody program expected to start in early 2021.

LEUVEN, Belgium, Oct. 22, 2020 /PRNewswire/ — ONCURIOUS NV, a Belgium-based biotech company focused on developing innovative immune-oncology treatments, today presents its strategy directed at boosting T cell migration, infiltration and activity into solid tumors, and announces that it has reached preclinical proof of concept and has entered the lead optimization phase with its proprietary CCR8 Treg program.

This important milestone follows Oncurious’ decision to focus its development activities on a pipeline of promising novel immune-oncology targets and drug discovery projects.

Oncurious scientists, in collaboration with world-class immuno-oncology experts in T cell and endothelial cell biology – Prof. Dr. Gabriele Bergers (VIB-KU Leuven), Prof. Dr. Massimiliano Mazzone (VIB-KU Leuven) and Prof. Dr. Jo Van Ginderachter (VIB-VUB), and the drug discovery unit at VIB, are building a pipeline of proprietary investigational I-O therapies with distinct mode of actions.

The team has discovered a potent and diverse panel of leads targeting human CCR8, has reached preclinical proof of concept and is entering the final lead optimization stages nearing preclinical candidate selection. Oncurious is now accelerating its efforts towards initiation of preclinical development of the therapeutic antibody program in early 2021.

CCR8 has been validated to be a tumor-infiltrating Treg-specific marker in solid tumors in both patients and animal models, making it the preferred target for therapeutic depletion of Tregs in cancer.

Oncurious’ CCR8 leads have been generated using an antibody technology platform that has been validated and used for more than a decade to generate high quality binders against G-protein coupled receptors. Molecules discovered using this technology were tested in several preclinical tumor models, and showed that targeting CCR8, depleted Tregs specifically in the tumor microenvironment and resulted in strong anti-tumor responses in monotherapy as well as in combination with anti-PD1. The treatments led to the establishment of immunological memory.

Next to the anti-CCR8 program, Oncurious is focusing on 2 other programs aimed at boosting anti-tumor T cell influx and activity in immune excluded tumors. Exclusion of T cells is an immunosuppressive mechanism commonly used by cancers to evade the immune system and as such is an attractive target for new therapeutic modalities.

The company expects to make further announcements regarding its progress in the near future.

Patrik De Haes, M.D., Executive Chairman of ONCURIOUS NV comments, “I am excited about the future of Oncurious based on its portfolio of novel, differentiated I-O therapies. The company’s approach is to generate novel drug candidates to treat immune excluded solid tumors that are not adequately addressed by immune checkpoint inhibitors, which are rapidly becoming the mainstay of cancer therapy. Today we are announcing significant progress in both hit and lead generation against novel I-O targets, including CCR8, which we believe could play a key role in the development of innovative immunotherapies to overcome solid tumor resistance. Working with leading scientists in the field, we aim to be at the forefront of a new wave of the I-O revolution and are confident that by delivering on our goals we can build Oncurious into a company of significant value in the years ahead. We look forward to updating you on our further progress.”

Jérôme Van Biervliet, Managing Director at VIB comments: “We are very pleased to see Oncurious’ anti-CCR8 antibody reach this important step towards preclinical development, not least thanks to the model collaboration with VIB Discovery Sciences.  Side-by-side with the Oncurious team, they are accelerating a promising pipeline of investigational immuno-oncology therapies.”

For further information please contact:

Oncurious NV

Wouter Piepers,

Investor Relations

& Corporate Communications

Tel: +32 478 33 56 32

[email protected] 


Elisabeth Stes

External Relations Manager

+32 9 244 66 11 / +32 486 82 59 02

[email protected] 

Citigate Dewe Rogerson

David Dible/ Sylvie Berrebi/Frazer Hall

Tel: +44 20 7638 9571

[email protected]



Oncurious is a Belgium-based biotech company focused on developing innovative oncology treatments derived from a series of promising new targets that are designed to enhance T cell activity, migration and influx into resistant tumour sites, boosting the patient’s own immune response against cancer. The company’s lead immune-oncology asset is a Treg-depleting asset, targeting a protein specifically expressed on Tregs in the tumour microenvironment. The program is in lead optimization. The company’s two other programs are focused on T cell migration and are in the discovery stages. 

Immuno-oncology made a major step forward in the treatment of cancer with the advent of immune checkpoint inhibitors, which are expected to represent a market opportunity of $50bn by 2025 (GlobalData 2020). Despite this clinical and commercial success, there remains an important need to develop new I-O approaches that improve efficacy, overcome resistance, and that can synergize with checkpoint inhibitors so that more patients with solid tumors can benefit from these life-saving therapies.

Oncurious’ early stage pipeline of novel immune-oncology programs offer the potential to overcome tumor resistance mechanisms, that current immune checkpoint inhibitors cannot address, and thereby significantly enhance the responses to immunotherapy across multiple tumor types.

More information: www.oncurious.com

About VIB

VIB is an excellence-based entrepreneurial research institute in life sciences located in Flanders, Belgium. VIB’s basic research leads to new and innovative insights into normal and pathological life processes. It unites the expertise of all its collaborators and research groups in a single institute, firmly based on its close partnership with 5 Flemish universities (Ghent University, KU Leuven, University of Antwerp, Vrije Universiteit Brussel and Hasselt University) and supported by a solid funding program from the Flemish government.

VIB has an excellent track record on translating basic scientific results into pharmaceutical, agricultural and industrial applications. Since its foundation in 1996, VIB has created 25 start-up companies, now employing over 900 people. The link between basic research and valorisation has made VIB a catalyst for the ever-growing biotech hotspot in Flanders. In recent years, numerous biotech companies — both large and small — have settled down in the region, thanks to top-notch infrastructure set up and provided by VIB and the ready availability of new scientific talent from the VIB labs.

More information: www.vib.be

SOURCE Oncurious NV

Montana nursing home sued for negligence in COVID-19 deaths

Montana nursing home sued for negligence in COVID-19 deaths

  • October 22, 2020

MISSOULA, Mont. (AP) — A long-term care facility in Montana has been sued after health officials said its staff was negligent and allowed the coronavirus to spread through the facility in Whitefish earlier this year.

The Missoulian reported that the lawsuit was filed Tuesday by the estates of three residents at Whitefish Care and Rehabilitation who died from complications caused by COVID-19.

The lawsuit argued that at least 13 people died at the facility.

The county had 23 coronavirus-related deaths.

The lawsuit named the 100-bed long-term care facility and its administrator Reid Crickmore.

Crickmore did not respond to email or phone messages on Wednesday seeking comment.


7 Ways to Give Your Immune System a Boost in Winter

7 Ways to Give Your Immune System a Boost in Winter

  • October 22, 2020

When the days get short and the weather gets chilly, the last thing you want is to be slowed down by a cold. Giving your immune system the support it needs can help give your body a fighting chance against illnesses like the common cold and flu (have you gotten your flu shot yet?). Here’s how.

7 Ways to Give Your Immune System a Boost in Winter
Herbaland’s gummies are gelatin- and sugar-free. | Herbaland

How Do You Boost Your Immune System?

The body’s first line of defense against germs and bacteria is a healthy lifestyle. This looks like enough sleep, regular exercise, frequent hand-washing, avoiding smoking, reducing stress, and a healthy diet. What they say about vitamin C’s ability to help fight colds is true—but it’s not the only important nutrient. Vitamin B6, vitamin C, vitamin E, magnesium, and zinc play key roles in maintaining a strong immune system.

Vitamin and mineral deficiencies can weaken the immune system, so it’s important to ensure that you’re eating a healthy diet rich in fruits and vegetables. But, many still struggle with doing that. If you suspect that you’re not getting enough, then daily supplements or superfood powders made from whole food ingredients can help meet your body’s needs. As always, consult your doctor before starting any new supplement. Here are some of our recommendations:

7 Ways to Give Your Immune System a Boost in Winter
The Immune Plus Gummies for Adults are made with echinacea and elderberry. | Herbaland

1. HerbaLand

Taking your daily vitamins can be easy to forget, but it can be critical going into cold and flu season. Founded in 2009, Canadian brand Herbaland saw a gap in the gummy vitamin market. So, they jumped in and made gummy vitamins that are vegan, sugar-free, dairy-free, soy-free, palm oil derivative-free, nut-free, halal, and kosher. Plus, they made them taste good enough to mistake for candy and ensure that their ingredients are sustainable, plant-based, and organic whenever possible. The company also ensures that its production processes are as kind to the planet as possible, from seeking zero-waste packaging solutions to its Eco-Forming process for depositing gummies into steel molds.

Herbaland’s Immune Plus Gummies for Adults are made with antioxidant-rich ingredients that help fight cold symptoms while giving your immune system a boost. These vegan gummies (no gelatin here!) contain a powerful blend of vitamin C, elderberry, and echinacea, which work together to support the body’s ability to fight colds. These sugar-free gummies have a raspberry lemon flavor, making taking your daily vitamins practical, especially compared to regular pills and capsules.

Along with keeping your immune system in check, it’s important to ensure that you’re taking your vitamins. Enter the D3 & B12 Gummies for Adults. These sugar-free gummies contain vitamin D3, a powerhouse that helps support the immune system, boost energy, and maintain strong bones and teeth. Vitamin B12, which needs to be supplemented on a plant-based diet, plays a key role in the metabolism of every single cell in the body and red blood cell production. They’re sugar-free and have a delicious raspberry flavor.

7 Ways to Give Your Immune System a Boost in Winter
Your Super makes superfood mixes for water or your smoothie. | Your Super

2. Your Super

The story behind Your Super is personal. Co-founder Kristel de Groot began making superfood mixes for her fiancé Michael after he was diagnosed with cancer at age 24. The more the pair learned about the connection between diet and good health, the more determined they became to share their knowledge of healthy, whole food ingredients with the world. Your Super makes superfood blends—inspired by the ones Kristel made for Michael while he was in recovery—made with five to six organic, plant-based ingredients and no sweeteners, stevia, artificial flavors, fillers, preservatives, or additives.

The Immunity Bundle boosts the body’s first line of defense against germs and bacteria with four super-charged superfood mixes. Here’s what’s in it:

Super Green mix: Like an instant green juice, made with wheatgrass, barley grass, moringa, baobab, spirulina, and chlorella. One scoop is the equivalent of a handful of greens and it’s packed with micronutrients like vitamin C, potassium, and iron.

Forever Beautiful mix: A fruity blend for glowing skin made with antioxidant-rich ingredients like chia seed, acai, maqui, acerola, maca, and blueberry.

7 Ways to Give Your Immune System a Boost in Winter
Mix Golden Mellow with frothed plant-based milk for a latte. | Your Super

Golden Mellow mix: A slightly spicy blend of inflammation-fighting and stress-reducing ingredients: turmeric, ashwagandha, ginger, cinnamon, lucuma, and black pepper.

Magic Mushroom mix: A chocolatey drink that helps support the immune system and boost your mood with cacao, chaga and reishi mushrooms, ashwagandha, lucuma, and cinnamon.

This bundle also comes with a digital copy of Everyday Super Smoothies, featuring more than 25 recipes for healthy, whole food smoothies for any time of day.

Use the code LIVEKINDLY for 15 percent off your purchase.

7 Ways to Give Your Immune System a Boost in Winter
This herbal supplement was inspired by folk medicine. | Gaia Herbs

3. Gaia Herbs

The Immune Shine from Gaia Herbs is a powder blend made with ingredients used in folk remedies to support the immune system, including elderberry, ginger, astragalus, and maitake and chaga mushrooms. A study found that maitake, a mushroom that has been grown in China and Japan for centuries that’s also known as hen-of-the-woods in Western cuisine, has immune-enhancing effects. Chaga, a type of black mushroom, has traditionally been used to treat various ailments and illnesses in Russia and Eastern Europe. It blends easily into smoothies, plant-based milk, and other beverages.

7 Ways to Give Your Immune System a Boost in Winter
This vegan D3 supplement can help your body get vitamin D when the days get shorter. | Hum Nutrition

4. Hum Nutrition

When we trade hot, sticky, humid days for the cool, crisp fall air (and hot lattes, finally), we also lose some sunlight. Vitamin D, also known as the “sunshine vitamin,” has a surprising amount of benefits, including regulating the absorption of calcium and phosphorus and helping the immune system function properly. Your body produces vitamin D when it’s exposed to sunlight, it makes sense that so many peoples’ levels drop during winter. Hum Nutrition’s vegan Here Comes the Sun softgels contain vitamin D3 derived from lichen, a moss-esque organism that arises from a symbiotic partnership between algae and fungus on trees, rocks, and walls.

7 Ways to Give Your Immune System a Boost in Winter
This earthy mushroom blend pairs well with coffee and tea. | Four Sigmatic

5. Four Sigmatic

The Four Sigmatic Mushroom Blend Mix is a powdered drink mix with a slightly earthy flavor that’s best stirred into coffee or tea. It combines 10 organic mushrooms that have been used in traditional medicines for centuries: chaga, reishi, lion’s mane, cordyceps, shiitake, enokitake (a long, thin white mushroom that’s also delicious in stir-fries), agaricus blazei, mishima, and tremella.

7 Ways to Give Your Immune System a Boost in Winter
You can take this elderberry syrup straight or mix it with water. | myKind Organics

6. myKind Organics

The result of a team-up between actress and vegan activist Alicia Silverstone and wellness brand Garden of Life, myKind offers 100 percent vegan multivitamins and herbal supplements. The Elderberry Immune Syrup is a concentrated formula made from black elderberry, echinacea, vitamin C-rich amla berry, and zinc derived from organic guava. It’s sugar-free and you can take it by the spoonful or mix it with water of the flat or sparkling variety.

7 Ways to Give Your Immune System a Boost in Winter
Hilma’s Immune Support is made for mixing with hot water. | Hilma

7. Hilma

The Immune Support powder from Hilma is formulated with vitamin C derived from camu camu berry, echinacea, ginger, turmeric, zinc, ivy leaf extract, and no fillers. It blends easily into hot or cold water and has a refreshing lemon ginger flavor, so it’s like drinking a cup of tea (which means you absolutely should pair it with vegan cookies).

Remember: vitamin C and zinc can help support your immune system, but it can’t do the work alone. Sticking to good hand-washing habits all throughout winter is your body’s best line of defense against getting sick.

This is a sponsored post.

LIVEKINDLY is here to help you navigate the growing marketplace of sustainable products that promote a kinder planet. All of our selections are curated by the editorial team. If you buy something we link to on our site, LIVEKINDLY may earn a commission.

CCMB-incubated Hyderabad startup supplement claims to boost immunity against Covid-19

CCMB-incubated Hyderabad startup supplement claims to boost immunity against Covid-19

  • October 22, 2020

A startup incubated at the Centre for Cellular and Molecular Biology in Hyderabad has developed ‘CoronAid’ a novel nutraceutical claimed to boost immunity against Covid-19.

The food supplement is made from a mushroom type, Cordyceps militaris, which grows in the Himalayan region and is known for immune boosting and anti-oxidant components.

Read | Risk of catching Covid-19 on flights low, not zero: WHO

Clone Deals, a start-up incubated at the Atal Incubation Centre-Centre for Cellular and Molecular Biology (AIC-CCMB), has collaborated with another Hyderabad-based company, Ambrosia Food Company, to develop a combination of the mushroom powder with curcumin, an active ingredient in turmeric, to make CoronAid Anti-Viral Immunity Booster Oral Suspension, a statement from CCMB said on Thursday.

Cordycepin in the mushroom powder is known to prevent the formation of new DNA and RNA strands.

Also Read | What we know so far about how Covid-19 affects the nervous system

Clone Deals has collaborated with scientists from CCMB to establish the potency of cordycepin in stopping the growth of the Covid-19-causing coronavirus in a cell-culture system. The studies show that cordycepin inhibits the multiplication of coronavirus.

Clone Deals has expertise in large-scale production of the mushroom in a controlled environment for its medicinal use. Currently, the team has obtained the FSSAI approval for marketing and submitted proposals to the government of India for conducting clinical trials at three All India Institute of Medical Sciences in Nagpur, Navi Mumbai and Bhopal, to establish the safety of their formulation, the CCMB said.

With satisfactory results of the clinical trials, the product is expected to be available from December 2020 in most cities and towns, adding considerable protection against the virus.

“We are delighted to  support a start-up focused on developing indigenous natural products and adding value by establishing its scientific basis,”   Dr Rakesh Mishra, director CCMB said.

Veritas Farms Signs Memorandum of Understanding With Pure Research Products, LLC to Access and Incorporate its Immune Technology in the Development of Additional Veritas Farms Products; Initiates Research Partnership

Veritas Farms Signs Memorandum of Understanding With Pure Research Products, LLC to Access and Incorporate its Immune Technology in the Development of Additional Veritas Farms Products; Initiates Research Partnership

  • October 22, 2020

Fort Lauderdale, FL, Oct. 22, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Veritas Farms, Inc. (OTCQB: VFRM) (“Veritas Farms” or the “Company”), a vertically integrated agribusiness focused on the production of full spectrum hemp oil products with naturally occurring cannabinoids, is pleased to announce that the Company has entered into a memorandum of understanding (the “MOU”) with Pure Research Products, LLC (“Pure Research”) to access and incorporate the technology used in their Del-Immune V® brand of products to develop additional Veritas Farms full spectrum hemp oil products.

Del-Immune V® and the Del-Immune line of dietary supplements use the probiotic strain Lacticaseibacillus rhamnosus (L. rhamnosus) [WF1] to boost immune function in the body. Pure Research’s proprietary formulation utilizes fragmented cells, specifically the cell wall and DNA, from the probiotic bacteria to trigger an immune modulation that boosts, strengthens, and fine-tunes the immune system. Del-Immune V® is one of the leading non-prescription cell fragment nutritional supplement supported by clinical research available in the United States.

The MOU, which was signed on October 8, 2020, establishes a partnership with Pure Research to maximize the benefits of Veritas Farms’ product line through the research, development and production of a Del-Immune V® enhanced line of full spectrum hemp oil products.

“The opportunity for Veritas Farms to develop full spectrum hemp products with clinically-supported immune-boosting biotechnology offers a new, innovative, powerful use for consumers to utilize hemp oil in their health routines,” Dr. Dan Connors, Vice President of Research and Development, stated. “The combination of Del-Immune V® and our full spectrum hemp oil products provides us with the potential to develop a diverse line of immune support products,” he concluded.

The collaboration will endeavor to research, develop, produce, and validate the efficacy of Del-Immune V® enhanced full spectrum hemp oil products. Products that are developed through the collaboration will be co-branded “Powered by Del-Immune.” The collaboration is subject to, among other matters, the negotiation and execution of a definitive collaboration agreement.

Alexander Salgado, CEO and Co-Founder, said, “We are excited to begin this research and development partnership with Pure Research Products. We strive to provide consumers with the products they need to live their healthiest lives, and now more than ever immune support is on everyone’s mind.”

“With decades of experience and research behind Del-Immune V® and our probiotic products for humans and animals, and our understanding of current scientific research and evidence of cannabinoid receptors in gut microbiota, we are confident that we will not only innovate new products in the space but lead the market,” said Dr. Liubov Sichel, CEO and Chief Scientific Officer of Pure Research.

About Veritas Farms, Inc.

Veritas Farms, Inc. (OTCQB: VFRM) is a vertically integrated agribusiness focused on producing superior quality, whole plant, full spectrum hemp oils, and extracts containing naturally occurring cannabinoids. The Company currently owns and operates a 140-acre farm and production facility in Pueblo, Colorado, and is registered with the Colorado Department of Agriculture to grow industrial hemp. The Company markets and sells products under its Veritas Farms™ brand and manufactures private label products for a number of leading distributors and retailers. 

Veritas Farms™ brand full spectrum hemp oil products include vegan capsules, tinctures, formulations for sublingual applications, and infused edibles, lotions, salves, and oral syringes in a variety of size formats and flavors. All Veritas Farms™ brand products are third-party laboratory tested for strength and purity. The Company files periodic reports with the Securities and Exchange Commission, which can be viewed at www.sec.gov.

For additional information and online product purchase, visit www.theveritasfarms.com.

About Pure Research Products, LLC

Pure Research Products, LLC was co-founded in 2002 by scientist Dr. Liubov Sichel with the intent of delivering natural immune support products based on various strains of bacteria including lacticaseibacillus rhamnosus (L. rhamnosus) which, in extracted form, is found in Del-Immune V®. Dr. Sichel developed Del-Immune V®, a fast-acting, broad-spectrum immune support supplement, based on one of the most effective microbial cell lysates used to treat a range of conditions in both humans and pets. It is the leading non-prescription cell fragment supplement backed by clinical research on the U.S. market.

Del-Immune V® is an immunomodulator that supports the immune system’s ability to help protect against all kinds of pathogens and foreign threats and provides immediate immune support. 

In addition to Del-Immune V®, Pure Research Products, offers a full line of human and pet immune support supplements. Pure Research Products, which serves customers globally, is based in Boulder, Colo., and the Del-Immune V® products are manufactured in Greenfield, Ind.

For more details on Del-Immune V ®and Pure Research Products’ full line of human and pet immune support supplements, visit: www.delimmune.com and follow @delimmunev on Facebook, Instagram and Twitter.

Veritas Farms, Inc. – Investor Contact

Toll-Free: 833-691-4367

E-mail: ir@theveritasfarms.com

Veritas Farms, Inc. – Social Media

Instagram:  www.instagram.com/veritasfarmsofficial/ 

Facebook: www.facebook.com/VeritasFarmsOfficial/  

LinkedIn: www.linkedin.com/company/veritasfarms/

Twitter: www.twitter.com/theveritasfarms  

Cautionary Language Concerning Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.  All statements, other than statements of historical fact, including those with respect to the Company’s mission statement and growth strategy, are “forward-looking statements.”  Although the Company’s management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct.  These forward-looking statements involve many risks and uncertainties, which could cause the Company’s future results to differ materially from those anticipated.  Potential risks and uncertainties include, among others, general economic conditions and conditions affecting the industries in which the Company operates; the uncertainty of regulatory requirements and approvals; and the ability to obtain necessary financing on acceptable terms or at all.  Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company’s filings with the Securities and Exchange Commission.  The Company assumes no obligation to update any of the information contained or referenced in this press release.

TN stands first in country in attracting foreign investments in 2020 : CM

Clone Deals launches ‘CoronAid’ to boost immunity against COVID-19

  • October 22, 2020
More News

22 Oct 2020 | 5:06 PM

Thoothukudi, Oct 22 (UNI) Vilathikulam police in this district on Thursday registered cases against two MLAs belonging to the ruling AIADMK and opposition DMK, besides 600 cadres of both parties in connection with a scuffle over hoisting party flag.

see more..

22 Oct 2020 | 5:02 PM

Hyderabad, Oct 22 (UNI) In a record breaking feat on South Central Railway (SCR), the Rail Vikas Nigam Limited (RVNL) has completed and commissioned doubling of 69 kms Railway line between Uppaluru-Gudivada-Moturu and Gudivada-Machilipatnam sections in Andhra Pradesh, on Thursday.

see more..

22 Oct 2020 | 4:53 PM

Puducherry, Oct 22 (UNI) Former Lok Sabha member from Puducherry Prof M.Ramadass on Thursday urged Lt.Governor Kiran Bedi and Chief Minister V Narayanasamy to take steps to hold the local body election in the Union Territory.

see more..

22 Oct 2020 | 4:28 PM

Visakhapatnam, Oct 22 (UNI) The Indigenously built INS Kavaratti (P31), an Anti-Submarine Warfare (ASW) stealth corvette built under Project 28 (Kamorta Class) was commissioned into the Indian Navy by Chief of the Army Staff General Manoj Mukund Naravane at a ceremony held at Naval Dockyard here on Thursday.

see more..

TN stands first in country in attracting foreign investments in 2020 : CM22 Oct 2020 | 4:24 PM

Pudukottai, Oct 22 (UNI) Tamil Nadu Chief Minister Edappadi K Palaniswami on Thursday said the state stood first in the country in attracting foreign investments in 2020.

see more..

12 ways to balance your immune system this winter

12 ways to balance your immune system this winter

  • October 22, 2020

“Immune ‘boosting’ is a phrase that I really can’t get on with,” says leading nutritional therapist and healthy eating expert, Amelia Freer, when asked about the best immune-boosting advice for the coming winter months. In fact, according to Freer, we’ve been approaching it all wrong—and when it comes to our immune system, the aim isn’t to boost, but rather to balance it.

An overactive immune system can result in auto-immune disease, or a significant widespread inflammatory state, while an under-active or otherwise compromised immune system can increase our risk of infection—neither of which is ideal. “In the simplest of terms,” says Freer, “we want to be able to switch our immune function on appropriately, and then switch it off again when the infection risk has passed.”

As for how we can do this best, Freer suggests nurturing and supporting our overall health and wellbeing. “There are various nutrients that our body requires to mount and suppress an appropriate immune response,” she comments. “The best way to get these is through eating a balanced, nutritious and abundant diet, so including a wide variety of different whole foods into our diets throughout the winter is a great place to start.”

Variety of fresh green vegetables.


1. Load up on dark-green vegetables

“First up is dark-green vegetables such as kale, chard, spinach, rocket, Brussels sprouts, sprouting broccoli. They all provide a variety of beneficial phytonutrients, fibre, Vitamin A, magnesium, folate and more. If there is one thing to add to our diets, it is this group of vegetables. Aim for at least one portion per day (remembering that when cooked, they tend to shrink considerably in terms of volume, making it easier to achieve this target).”

2. Opt for citrus fruits

“Citrus fruits are a good source of Vitamin C and perfect for the coldest winter months—a little bit of concentrated sunshine just when we need it most. I particularly love the month or two that blood oranges are available [around December to April]—I have one almost every day when I can, as the most deliciously simple dessert.”

Citrus fruits. Oranges, grapefruits and mandarins.

© Getty

3. Make room for mackerel

“This is a cheap and readily available oily fish and a source of long-chain omega-3 fatty acids, which can help to regulate inflammation in the body. It also contains some food-based Vitamin D, as well as protein, and it’s a great speedy choice for lunches. Top tip: look out for unsmoked, frozen mackerel fillets in the freezer section of some supermarkets. I’ve found that it’s the best fish to cook from frozen, and contains less salt than the smoked version.”

4. Swap in some squash or pumpkin

“There are a huge variety of orange-fleshed pumpkins to enjoy over winter. They provide a source of Vitamin A, which, as a fat-soluble vitamin, is best absorbed alongside some healthy fats. I therefore tend to slow-roast my squash and pumpkins in a little olive oil, and then enjoy as they come, blended into sauces or soups, or tossed into salads with rocket, radicchio, some toasted hazelnuts and crumbled feta.”

5. Balance your diet with Brazil nuts

“Brazil nuts are a key source of the micronutrient selenium, which is an important mineral for optimal immune response. Just four or five Brazil nuts per week can meet our selenium requirements. It is, however, one of the few whole food nutrients that we can over-consume, so it’s best to mix things up and eat just a few each week alongside a variety of other nuts and seeds, too.”

6. Choose chickpeas or other pulses

“I adore pulses in all shapes and sizes, and I find them a convenient source of protein—I aim to have roughly a palm-sized portion of protein at each meal of the day. Protein is important for enabling the body to mount an appropriate immune response, as well as for repair and growth of our body’s tissues, and for appetite and blood-sugar regulation. I buy pulses in bulk in jars and add them to soups, make them into hummus and other dips, throw them into curries and stews, or eat them cold with some olive oil, lemon and a few chopped herbs.”

Steamed mussels 

© fcafotodigital

7. Switch to shellfish

“Shellfish is a good source of zinc and Vitamin B12, and mussels and scallops are in season over the winter months. They are a bit of a treat, but it’s worth making the effort to cook them once in a while. Do check that they are sustainably sourced and if you’re unsure about cooking them yourself, it might be a good option to consider ordering if eating out.”

8. Start soaking your own oats

Rolled oats are a great choice and can provide not only a warming and delicious porridge breakfast, but also a hefty dose of fibre, too. Soaking oats overnight can help to make the nutrients they contain more absorbable, as well as speeding up the cooking time.”

A single poached egg on artisan hand sliced toasted bread. 

© Jody Louie took this picture

9. Introduce more eggs

“Eggs are such a versatile and useful ingredient to have on hand for quick meals and speedy snacks. They are also a source of Vitamin B12, a little Vitamin D, Vitamin A, protein and some are even fortified with omega-3 fatty acids, all of which are important for balanced immune function.”

10. Drink lots of water

“Maintaining a good level of hydration can help to keep our mucosal barriers moist, such as those in our mouth and the lining of our nose. This might sound strange, but hydration of these tissues helps to support the natural immune function that exists within them, warding off infection before it has a chance to enter the body. Plus water won’t spoil your appetite for the abundance of nourishing whole foods awaiting you at your next meal.”

11. Increase your Vitamin D

“The only supplement that is recommended for everyone to consider over the winter months is Vitamin D. In some countries, the sunlight is not strong enough between October and early March for our skin to make enough Vitamin D to meet our requirements.”

12. Optimise other aspects of your lifestyle

“I know it’s been said a thousand times before, but it really is what works: wash your hands, prioritise sleep, actively respond to and manage stress, move regularly, exercise, moderate alcohol and avoid smoking. It’s not original, but it is effective.”

Also read:

6 ways to bolster your immune system against COVID-19 if you’re in your 60s and older

Malaika Arora uses these Indian ingredients to make a homemade immunity-boosting tonic

Can food really help you build immunity against diseases?

Can B Corp. Partners with Dr. Karl Zarse to Launch ImmuneX2 Other OTC:CANB

Can B Corp. Partners with Dr. Karl Zarse to Launch ImmuneX2 Other OTC:CANB

  • October 22, 2020

Optimizing Your Immune System Before You Need It

HICKSVILLE, NY, Oct. 22, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Can B Corp. (OTCQB: CANB) (“Can B” or the “Company”), diversified health and wellness company is pleased to announce its collaboration with Dr. Karl Zarse in launching ImmuneX2, a super immune boosting AM/PM supplement.  According to Dr. Zarse, ImmuneX2 ingredients are correlated with optimizing your immune system before you need it. The Company is expecting to start shipping ImmuneX2 by the end of November.

ImmuneX2 is a high concentration immune booster and is positioned for AM/PM dosing for consistent serum concentration. It’s pre-packaged for maximum convenience and offers free member access for ongoing education that updates in real-time.

The physician-developed immunity optimization formula has both innate and adaptive immune functionality specifically targeted with ImmuneX2’s proprietary customer blend focused on immune system optimization. According to Dr. Zarse, no other product exceeds the dosages of this blend while avoiding any issues of toxicity. It can compensate for variations in the client base including malabsorption issues, size differences, and baseline health status. Maximum benefit is obtained not only by staying adherent to the daily supplement line but also by following and learning an online education program.

Marco Alfonsi, Can B’s Chief Executive Officer, commented, “We are really excited to have this opportunity to bring to market such a unique, powerful, and needed product such as ImmuneX2. Dr. Zarse states that he and his team have come up with a supercharged proprietary immunity blend. Our fulfillment operations in Lacey, Washington, just outside of Seattle, are ramping up preparation for expected substantial production. Our current and expanding distribution network, especially the medical offices and doctors, are prime candidates to start accepting shipments by the end of November.”

Dr. Karl Zarse stated, “It’s been an absolute pleasure working with such a professional team at Can B Corp. and its Pure Health division. This collaboration and strategy have made my dream come true in having an immune-boosting system widely available to the public. I think it’s going to be a game-changer as to why keeping an optimized immune system is so important in order to live a healthy lifestyle. I look forward to working closely with Can B in producing ImmuneX2 and distributing it through their existing sales channels and ever-expanding network.”

Dr. Karl Zarse is the founding member of Idaho Spine and Pain. He is certified by the American Board of Interventional Pain Physicians and travels throughout the country to bring his patients the most advanced therapies available. For additional information on Dr. Karl Zarse, please visit http://www.idahospineandpain.com.

The statements made herein have not been evaluated by the FDA. ImmuneX2 is not intended to diagnose, treat, cure, or prevent any disease.

About Can B Corp.

Can B Corp. (OTCQB: CANB) is a Health & Wellness company providing the highest quality cannabidiol (CBD) products under the brands of Canbiola, Seven Chakras, NuWellness, Pure Leaf Oil, and Duramed. Can B utilizes multi-channel distribution to reach consumers, including medical facilities, doctor offices, retailers, online and direct. Can B is also an exclusive partner of the LifeGuard® Brand in developing a line of consumer products. The Company is also launching Super Foods, a line of nutritional supplements. Can B Corp. owns and operates an R&D and production facility in Lacey, WA, and Green Grow Farms, a licensed hemp grow and cultivation in New York. To learn more about Can B Corp. and our comprehensive line of high-quality CBD products, please visit: Canbiola.com and www.CanBCorp.com, follow Can B Corp on Instagram and Facebook, or visit one of the 1,000+ retail outlets that carry Can B Corp. products.

For more information about Can B Corp., please visit: CanBCorp.com

Twitter @CanBCorp

Instagram @canbcorp

Facebook @ Can B Corp

Forward-Looking Statements

Forward-looking statements and risks and uncertainties discussed in this release contain forward-looking statements. The words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect,” and similar expressions identify such forward-looking statements. Expected, actual results, performance or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape, or manner of our future financial condition or stock price. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

Investors and Media:


(646) 397-2309

boost immunity, coronavirus, COVID-19, food for immunity, drinks for immunity

6 healthy drinks to boost your immune system

  • October 22, 2020

Falling sick is not a risk you should be taking at times like these. For keeping diseases at bay, you need to boost your immune system, which requires eating the right nutrition. The antibodies present in our immune system combat diseases, infections, and it is important that you keep it healthy and strong. The pandemic has made us realize the importance of immunity in our daily lives. A study conducted by the University of Melbourne found that a strong immune system can fight the virus and help you recover from the infection. If you too wish to build strong immunity, these 5 drinks might be able to help you. Also Read – COVID-19 vaccine trials can’t tell if the shots will save lives, protect the elderly

Tomato juice

Fresh tomato juice contains folate, which alleviates the risk of infections. It also provides a wide variety of vitamins, minerals and potent antioxidants that provide the body with numerous health benefits. All you have to do is cook sliced tomatoes for about thirty minutes over medium heat and toss into a food processor and blend it until it reaches the desired consistency. Also Read – Volunteer in Oxford Covid-19 vaccine test dies in Brazil, but trial continues

Vegetable-based green juice

Mix green apple, lettuce and kale in a blender and mix well – this is a great immunity-boosting drink that you can add to your daily diet. Apple skins contain a type of plant pigment flavonoid known as quercetin that helps strengthen the immune system and reduce inflammation. Lettuce and kale, on the other hand, contain vitamin C, a powerful antioxidant that helps fight off infection and boost your immune system. Also Read – COVID-19 Live Updates: Cases in India surge to 77,06,946 while death toll reaches 1,16,616

Red fruit juice

Bring the goodness of beetroot, carrot, ginger and apple into a single glass. This drink is a powerhouse of nutrients that will decrease inflammatory symptoms and help your immune system. Not only this, but it also helps you deal with cold or flu symptoms, which can hinder your everyday work.

Citrus fruit juice

Citrus fruits are touted as the best sources of vitamin C and strong immunity boosters. What you might not know is that vitamin C increases the production of white blood cells, which helps your body fight against infections and viral diseases. Vitamin C deficiency has long been associated with the impairment of immune response. For a healthy adult, 200 mg a day is enough to boost the immune system.

Watermelon juice

Watermelon has a high content of water that keeps your body hydrated. It also helps in detoxification. It contains healthy nutrients like vitamin C, vitamin A and magnesium. Not only that, but it also helps relieve muscle soreness, which is a common symptom of flu.

Pumpkin juice

Prepared with pumpkin seeds, this juice is high in zinc, magnesium and fiber, three of the essential nutrients required to maintain a healthy immune system. It also helps decrease inflammation. To prepare this healthy drink, all you need is a cup of pumpkin seeds soaked overnight, filtered water and a pinch of salt. Blend it for about 30 seconds, until the seeds are fully pulverized. Strain it and drink.

Published : October 22, 2020 1:51 pm

Evive Biotech meets primary and secondary endpoints in global Phase III clinical trial for their novel chemotherapy-induced neutropenia treatment | Proteins and Peptides

GSK presents positive clinical data on maternal and older adults RSV candidate vaccines | Vaccines

  • October 22, 2020

GSK presents positive clinical data on maternal and older adults RSV candidate vaccines

  • Phase I/II data presented at ID Week show that the two FDA fast-tracked candidate vaccines trigger robust immune response and are well-tolerated
  • There is currently no vaccine for respiratory syncytial virus (RSV), which causes significant morbidity and mortality in infants and older adults
  • Phase III studies are on track to start in the coming months 

LONDON, UK I October 21, 2020 I GSK today announced that its Respiratory Syncytial Virus (RSV) candidate vaccines for maternal immunisation (GSK3888550A) and older adults (GSK3844766A) were well-tolerated and highly immunogenic in Phase I/II clinical studies. The data were presented virtually at the ID Week Congress.

RSV is a leading cause of respiratory infections such as bronchiolitis (inflammation and congestion of the small airways or bronchioles of the lung) and pneumonia (an inflammatory condition of the lung small air sacs or alveoli) in infants and older adults. It is estimated to cause about 3 million hospitalisations of children under 5 year of age globally[1], and 177,000 hospitalisations of older people in the US alone[2].

Both candidate vaccines contain a recombinant subunit pre-fusion RSV antigen (RSVPreF3) which is believed to trigger the required immune response. The vaccine for older adults also includes GSK’s proprietary AS01 adjuvant system[3] to boost the immune response as this population tends to show weaker immune response to vaccination than younger adults.

The vaccine candidate for older adults was first tested in 48 healthy adults (18-40 years old) and then in 1,005 healthy older adults (60-80 years old) with different dosages of antigen and adjuvant compared with a placebo. The interim data 1-month post-immunisation show that:

  • the candidate vaccine elicited a robust humoral and cellular immunity compared with baseline
  • a close to 10 times increase of protective antibodies (RSVPreF3 IgG and RSV-A neutralising antibodies) was induced in the vaccinated group
  • importantly, the cellular immunity (RSVPreF3-specific CD4+ T-cells) of the vaccinated older adults was boosted to reach similar range to that observed in the younger adults after vaccination with the non-adjuvanted formulation, despite the initial lower baseline level observed in older adults compared with young adults.

The maternal RSV candidate vaccine was tested with 3 different doses compared with placebo in 502 healthy non-pregnant women over monthly visits (Day 8, Day 31 and Day 91 post immunisation). The data show that, compared with baseline:

  • the investigational vaccine was able to rapidly boost the pre-existing immunity at all dose levels, leading to high levels of protective neutralising antibodies
  • at Day 8, a 14-fold increase in RSV-A and RSV-B neutralising antibodies titers was observed.

These two vaccines are part of a tailored, portfolio approach GSK is pursuing with three RSV candidate vaccines – maternal, paediatric and older adults – using different novel technologies aiming to help protect the populations most impacted: infants and older adults. All three candidate vaccines have received FDA fast-track designation.

Emmanuel Hanon, Senior Vice-President and Head of Vaccines R&D, said: “RSV is an infectious disease that can have a very serious impact on families and societies. We are delighted to see these positive results confirming our approach to develop dedicated vaccines building on the strategic use of our platform technologies for the populations most at risk from RSV infections – young infants and older adults. Our portfolio strategy takes into account the unique needs of the immune system of these vulnerable populations and we look forward to progressing these assets to Phase III trials to evaluate their potential efficacy”.

Vaccines for RSV prevention could lead to significant reductions in disease, doctor’s visits, and hospitalisations in infants, toddlers, and older adults, thus having the potential for a significant benefit to individual health in the most vulnerable populations as well as a positive impact on the burden and costs of healthcare systems around the world.

Based on available data and engagement with regulators, Phase III studies for both older adults and maternal RSV candidate vaccines are in preparation and on-track to start in the coming months, while the Phase I/II (in RSV-seronegative infants) and Phase II (in RSV-seropositive infants) studies with the paediatric RSV candidate vaccine are ongoing. Phase I/II safety and immunogenicity data on the paediatric RSV candidate vaccine in RSV-seropositive infants will be presented at European Society for Paediatric Infectious Diseases (ESPID) on 26-29 October 2020.

About GSK’s RSV candidate vaccine for older adults (GSK3844766A)

The Phase I/II study investigates the safety, reactogenicity and immune response of GSK’s RSV candidate vaccine  in older adults aged 60 to 80 (NCT03814590). This candidate vaccine contains GSK’s proprietary AS01 adjuvant, which is also used in GSK’s shingles vaccine. The safety, reactogenicity and immune responses (humoral and cellular-mediated) were first assessed in 48 healthy adults aged 18–40 years who were vaccinated with either 30, 60 or 120 μg dose level of RSVPreF3 non-adjuvanted vaccine or placebo. Following favourable safety outcomes, 1005 adults aged 60–80 years were randomised in a 2-step staggered manner to receive 1 of the 9 RSV vaccine formulations containing either 30, 60 or 120 μg dose level of RSVPreF3, non-adjuvanted or adjuvanted with AS01E or AS01B, or placebo.

Interim data presented at ID Week show that within one-month post-immunisation, the adjuvanted candidate vaccine has been well tolerated with no safety concerns identified. The most frequently reported adverse events were pain at injection site, fatigue and headache.

Moreover, data 1-month post-immunisation show that the candidate vaccine elicited a robust humoral and cellular immunity compared with baseline:

  • High levels of RSVPreF3 IgG antibodies (geometric mean antibody concentrations were 8.4–13.5 for the 18-40 year old vaccinees, and 7.2–12.8 fold-higher in the 60–80-year-old vaccinees) and RSV-A neutralising antibodies (geometric mean antibody titers were 7.5–13.7 in the 18–40 year old vaccinees, and 5.6–9.9 fold-higher in 60–80-year-old vaccinees) were induced in all vaccinated groups.
  • Before vaccination, deficiency of RSVPreF3-specific T-cells (hypothesised to help promote viral clearance) was observed in older adults compared to younger adults. After vaccination, a robust RSVPreF3 CD4+ T-cells response in older adults had been boosted to reach a similar range than the one observed in younger adults, with significantly higher immune response in the groups who received the adjuvanted formulation.

About GSK’s maternal RSV candidate vaccine (GSK3888550A)

The goal of this candidate vaccine is to prevent RSV-associated lower respiratory tract infections in infants during the first months of life by transfer of maternal antibodies – an approach based on GSK’s strong expertise in maternal immunisation acquired through pertussis and flu vaccine programmes. The polyclonal nature of the humoral response boosted by this vaccine could potentially offer broad protection across a large number of RSV strains and addressing the potential issue of virus escape mutation. Maternal immunisation could help to protect infants too young to be immunised from RSV-associated infections in their first months of life – when they are the most vulnerable – without any medical intervention required thanks to the passive transmission of neutralising antibodies from the vaccinated mother to the unborn child in the last weeks of pregnancy.

In this Phase I/II study (NCT03674177), 502 healthy non-pregnant women received 1 dose of either 30, 60 or 120 μg of recombinant protein-based RSVPreF3 or placebo. The safety, reactogenicity and immunogenicity was monitored for 6 months. The data 1-month post-immunisation show that all vaccine dose levels were well-tolerated, with no safety concerns identified: the most frequently reported solicited adverse events were minor and included pain at injection site and headache. 

Moreover, the data show that the candidate vaccine elicited a rapid and persistent immune response in all RSVPreF3 groups. The immune response peaked at Day 8 with a 14-fold increase in neutralising RSV-A and RSV-B titers from baseline. The neutralising titers declined over time but a >6-fold increase was still maintained at Day 91. Anti-RSVPreF3 IgG antibodies were boosted substantially in all groups with geometric mean concentrations of anti-RSVPreF3 IgG antibody (≥ 12-fold at Day 8 and ≥ 6-fold until Day 91 vs baseline). The 60 and 120 μg dose levels of RSVPreF3 were more immunogenic than the 30 μg formulation.

Safety and immunogenicity data from the first time in pregnant women study will be presented in the first half of 2021. The data currently available provide the confidence to advance to late stage clinical work.

About respiratory syncytial virus

Globally, there are an estimated 33 million cases of RSV annually in children less than 5 years of age, with about 3 million hospitalised and approximately 120,000 dying each year from complications associated with the infection. Nearly half of these pediatric hospitalisations and deaths occur in infants less than 6 months of age[4]. According to the Centers for Disease Control and Prevention, virtually all children in the US get an RSV infection by the time they are 2 years old and one to two out of every 100 children younger than 6 months of age with RSV infection may need to be hospitalised[5].

It also represents a significant health threat for older adults, with an estimated 177,000 hospitalisations and 14,000 deaths associated with RSV infections occurring in the US alone[6]. Without robust surveillance systems in several countries, global data on the burden of RSV in older adults is either lacking or likely to underestimate its significance. As global population ages, morbidity and mortality of respiratory infections including RSV to be steadily increasing.

About GSK

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com.


[1] Shi  T. et al, Lancet. 2017;390:946–58

[2] https://www.cdc.gov/features/rsv/index.html

[3] The GSK proprietary AS01 adjuvant system contains QS-21 StimulonTM adjuvant licensed from Agenus Inc. (NASDAQ: AGEN)

[4] Shi  T. et al, Lancet. 2017;390:946–58

[5] CDC – https://www.cdc.gov/rsv/high-risk/infants-young-children.html

[6] CDC – https://www.cdc.gov/features/rsv/

SOURCE: GlaxoSmithKline

Do NOT follow this link or you will be banned from the site!